Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Articles

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Day 4 Recap: AAD 2025

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more. 

 How to Avoid Complications With Radiofrequency and Ultrasound-Based Technologies 

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

Michael Gold, MD: Insights on Silicone, Energy-Based Devices, and Radiation Therapy

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.  

Advancing Medical Treatments for Vitiligo With Amit Pandya, MD, FAAD 

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Feeling burdened with administrative tasks, Michael Sherling, MD, MBA, found a way to make things easier not just for him, but for colleagues as well.

Sherling, chief medical and strategy officer and cofounder of health care information technology company ModMed, started the company 15 years ago after chatting with a patient, Dan Cane, who is a technologist.

“And after our skin check, we started the company,” he told 

. “It's designed to really save doctors and their staff time, which has really been our whole mission from the beginning.”

Michael Sherling, MD, MBA, leverages AI to simplify administrative tasks and focus on patient care.  

Dermatologist Creates Tool to Make Documentation Easier 

"ModMed Scribe is really cool," Sherling explained. "It's an AI-enabled technology built inside of our EMR that listens to a doctor and patient speak naturally and then predicts the note as if a person was typing on the iPad." The system not only transcribes conversations but can also offer the customary prescriptions, lab orders, biopsies, Botox units, and body locations—key elements in dermatology documentation.

He acknowledged some clinicians may be skeptical about inviting AI into the examining room. "We want to automate the drudgery of healthcare. Things like documenting notes, filling out encounter forms, and writing requisition forms—why should doctors have to do that? If AI can predict structured data and integrate it into the EMR, it’s incredibly helpful," he told 

"Recently, I’ve been volunteering in a clinic where I have no staff to help me. I do everything myself. This technology is a lifeline," he added.

Accuracy of the tool was very important to Sherling, who translated his appreciation of efficacy data in clinical practice to ensuring accuracy in the AI product via rigorous testing. "There’s something called an F1 score, which measures the accuracy of AI predictions. In our internal testing, the F1 score for dermatologic diagnoses is around 98.4%, so it’s very accurate," Sherling explained.

In addition to accuracy, Sherling is also dedicated to ensuring security, which remains a top priority for ModMed. "Our speech-to-text model is on-device, meaning the transcript stays inside the iPad, which is good from a security perspective,” he explained. “We train the model using only de-identified data—nothing that can identify a patient or doctor. And as an EHR company, we take security very seriously."

For Sherling, ModMed Scribe is more than just a technological innovation—it’s a solution designed by a dermatologist for dermatologists. "Being a dermatologist is my identity, but I also help my customers because I am a customer,” he said. “I use the products we develop, ensuring they meet the needs of physicians. At the end of the day, we want doctors to focus on treating patients. Everything else is just noise."

Dermatologist Creates AI Tool to Make Documentation Easier 

“This study we presented here for the first time is just dedicated to adolescents. It is the largest study of a JAK inhibitor dedicated to adolescents with severe alopecia areata,” said Anabela Cardoso, MD, in an interview at the 

2025 American Academy of Dermatology (AAD) Annual Meeting

Cardoso, the senior vice president of immunology medical affairs at Eli Lilly and Company, discussed pivotal findings on baricitinib (Olumiant; Lilly/Incyte) for adolescents with severe alopecia areata during an AAD late-breaker session. The data demonstrated that adolescent patients (aged 12 to 18 years) with severe alopecia areata treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at week 36.

The primary end point of the study was a Severity of Alopecia Tool score ≤20 (80% or more scalp hair coverage) at week 36. At the start of the study, patients had an average of 89% scalp hair loss (near total hair loss), 65% had minimal or no eyebrow hair (clinician-reported outcome [ClinRO] score of 2 or 3), and 57% had minimal or no eyelash hair (ClinRO score of 2 or 3).

Late-Breaking Data: Baricitinib Shows Rapid Hair Regrowth in Adolescents With Severe Alopecia Areata 

Alopecia areata affects both adults and adolescents, with approximately 40% of cases beginning before age 20. Early-onset disease carries a significant psychosocial burden, impacting self-esteem, social interactions, and mental health, making effective treatment crucial for this high unmet need population.

The phase 3 BRAVE-AA-PEDS trial was a dedicated adolescent study on baricitinib, the largest JAK inhibitor study for this population, and enrolled 250 patients with severe alopecia areata, many of whom had complete or near-complete scalp hair loss. Compared to adults, adolescents presented with more severe disease, yet baricitinib demonstrated faster efficacy in this group. At 36 weeks, approximately 60% of patients achieved ≥50% hair regrowth, a milestone that took one year in adults, highlighting potentially accelerated responsiveness in younger patients.

According to Cardoso, safety considerations were a key focus, given baricitinib’s status as a JAK inhibitor. The study’s safety profile was consistent with adult trials, reinforcing its potential as a well-tolerated option for adolescents. Cardoso noted baricitinib has been studied in over 800 patients aged 18 years, including those as young as 2 years old, and in more than 14,000 adults across various immune-mediated diseases.

The latest data shows baricitinib’s potential to fill a critical treatment gap for adolescents with severe alopecia areata, offering faster and effective hair regrowth with a well-established safety profile.

Passerson T. Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a phase 3 randomized, controlled trial. Presented at: 2025 American Academy of Dermatology Annual Meeting. March 7-11, 2025; Orlando, FL.

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study. News release. Eli Lilly and Company. March 8, 2025. Accessed March 8, 2025. 

https://investor.lilly.com/news-releases/news-release-details/lillys-baricitinib-delivered-high-rates-hair-regrowth

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

 Late-Breaking Data: Baricitinib Shows Rapid Hair Regrowth in Adolescents With Severe Alopecia Areata

Each year, dermatology clinicians have a plethora of conferences to attend across the US, and even internationally. Although you may not be able to attend them all, there is no shortage of new data presented at each conference. Specific meetings geared towards dermatology advanced practice providers are growing in both quantity and size. Just last month, the inaugural Inflammatory Disease Summit in Las Vegas, Nevada, kicked off an exciting first year. 

Out of the meetings listed below, which one did you enjoy the most? Or, email us at 

As we get ready to plan for a busy 2024, check back for additional meeting opportunities!

Fall Clinical Dermatology Conference for PAs & NPs

Society of Dermatology Nurse Practitioners

Society of Dermatology Physician Assistants

Dermatology Education Foundation (DEF) - DERM2023 NP/PA CME Conference 

DEF Biologic & Small Molecule NP/PA CME Bootcamp

Masterclasses in Psoriatic Disease Plus for APP+

Click here to answer this week's NP & PA poll. Out of the meetings listed below, which one did you enjoy the most?

Polls 

POLL: Which of the Following 2023 NP & PA Conferences Has Been Your Favorite?

“The most fun part of AAD for me every year is thinking about the fact that we've already seen everything that we expect in 'X' disease state. There can't possibly be more, right? And I'm usually wrong every year,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with 

Chovatiya, clinical associate professor at Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and a 

Editorial Advisory Board member, provided tips for early-career dermatologists attending the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, held March 7-11. He also shared content he looks forward to every year, including updates in atopic dermatitis, hidradenitis suppurativa, chronic spontaneous urticaria, and more.

At AAD, Chovatiya is presenting “Inflammatory Disorders Part 2: Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa” on Sunday, March 8, at 1:20 pm ET.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting. 

Early-Career Tips for Attending AAD 2025 

Reflecting on his early experiences, Chovatiya acknowledged how overwhelming larger meetings can be for young dermatologists, especially at AAD. His primary advice: prioritize key sessions and interests rather than attempting to cover everything.

Chovatiya emphasized that missing certain sessions won’t set anyone back in their career, but strategic planning is essential. Attendees should focus on topics that align with their clinical or research interests, whether that’s late-breaking clinical trial data, emerging therapeutic innovations, or deep dives into specific disease states. While networking, social events, and the exhibit hall have value, he encouraged attendees to structure their schedules around sessions that will advance their knowledge and shape their future practice.

A highlight of the AAD meeting for Chovatiya is the continuous evolution of dermatologic treatments. Each year, new developments emerge, particularly in areas such as atopic dermatitis, psoriasis, hidradenitis suppurativa, chronic spontaneous urticaria, vitiligo, alopecia areata, and chronic hand eczema. He noted that the landscape of dermatology has become so robust that even significant phase 2 and phase 3 clinical trials may not secure a spot in the late-breaking sessions at AAD due to the sheer volume of new data.

As a researcher and clinician, Chovatiya enjoys observing how therapies he has studied or followed closely advance through the clinical trial pipeline. He discussed the importance of staying updated on the latest data that will define future dermatologic treatment. Whether through direct participation in research or careful monitoring of new findings, he believes that understanding these developments is crucial for dermatologists aiming to provide the best care for their patients.

Overall, his message to younger dermatologists is to approach conferences with a balance of focus and flexibility. By strategically selecting educational opportunities, dermatologists can stay informed about the latest therapeutic advancements.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Early-Career Tips for Attending AAD 2025

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Adewole Adamson, MD, MPP: Getting Ready to Tackle Dermatology's Key Challenges Issues at AAD 2025

Adewole (Ade) Adamson, MD, MPP, FAAD, assistant professor in the Department of Dermatology at Dell Medical School, University of Texas at Austin, is preparing for this week's 

, which will take place from March 7-11 in Orlando, Florida. 

At the meeting, Adamson will be participating in 2 sessions: "Approach to Melanoma Diagnosis" and "The 2025 Debates: Controversies in Dermatology," both of which will take place on Friday, March 7. These sessions promise to tackle pressing issues in dermatology, with an emphasis on melanoma diagnosis and the ongoing challenges in the specialty.

In previewing the event, Adamson shared key insights on the areas of focus for this year's meeting, specifically regarding the importance of tackling controversies within dermatology.

Adamson, who directs the Melanoma and Pigmented Lesion Clinic at Dell Seton Medical Center, works closely with patients at high risk for melanoma. He expressed that "areas of controversy are where we can learn the most and push the field the most." This perspective will drive his participation in discussions centered on advancing the field through rigorous dialogue. 

As he emphasized, the AAD provides a platform for "vigorous discussions around things that matter to us all and matter to our patients."

These discussions will cover key topics such as improving diagnostic techniques and treatment approaches for melanoma, particularly for high-risk patients. Adamson’s clinical focus on melanoma management, combined with his research into pigmented lesions, will be central to his contributions at the meeting.

"The AAD is a chance to engage with colleagues and really push forward our understanding of critical dermatologic issues," Adamson said. "By addressing areas of controversy, we can challenge ourselves and ultimately improve patient outcomes."

Amit Pandya, MD

Articles

Latest Updated Articles